Takeda files NDA for diabetes drug
The new drug application (NDA) submission was supported by two Phase III clinical trials, involving more than 2,000 patients worldwide. The studies assessed the efficacy and safety of
Insilico Medicine has entered into a strategic collaboration agreement with Takeda to deploy its AI-based Pharma.AI platform in the discovery and development of drug candidates.